Quantitative Sciences Unit, Stanford University, Stanford, CA.
Quantitative Sciences Unit, Stanford University, Stanford, CA; Department of Population Health Sciences, Weill Cornell Medicine, New York, NY.
Clin Lung Cancer. 2024 Dec;25(8):705-711.e7. doi: 10.1016/j.cllc.2024.08.017. Epub 2024 Sep 6.
Long-term breast cancer (BC) survivors are known to develop second malignancies, with second primary lung cancer (SPLC) one common type. Smoking was identified as a main risk factor for SPLC among BC survivors. These findings were limited to the U.S. and focused on smoking status, not incorporating cumulative smoking exposures (eg, pack-years). We examine SPLC incidence and evaluate the associations between SPLC risk and cumulative cigarette smoking exposures and other potential factors among BC survivors in a prospective European cohort.
Of 502,505 participants enrolled in the UK Biobank in 2006 to 2010, we identified 8429 patients diagnosed with BC between 2006 and 2016 and followed for second malignancies through 2016. Smoking information was collected at enrollment, and treatment data were collected using electronic health records. Multivariable cause-specific Cox regression (CSC) evaluated the association between each factor and SPLC risk.
Of 8429 BC patients, 40 (0.47%) developed SPLC over 45,376 person-years. The 10-year cumulative SPLC incidence was 0.48% (95% CI = 0.33%-0.62%). The CSC analysis confirmed the association between SPLC and ever-smoking status (adjusted hazard-ratio (aHR) = 3.46 (P < .001). The analysis showed a 24% increment in SPLC risk per 10 smoking pack-years among BC survivors (aHR = 1.24 per-10 pack-years, P = .01). The associations between SPLC and other variables remained statistically insignificant. We applied the USPSTF lung cancer screening eligibility criteria and found that 80% of the 40 BC survivors who developed SPLC would have been ineligible for lung cancer screening.
In a large, European cohort, cumulative smoking exposure is significantly associated with SPLC risk among BC survivors.
已知长期患有乳腺癌(BC)的幸存者会发展为第二恶性肿瘤,其中第二原发性肺癌(SPLC)是一种常见类型。吸烟被确定为 BC 幸存者发生 SPLC 的主要危险因素。这些发现仅限于美国,且仅关注吸烟状况,并未纳入累积吸烟暴露(例如,包年数)。我们在一项前瞻性欧洲队列研究中检查了 SPLC 的发病率,并评估了 SPLC 风险与累积吸烟暴露以及 BC 幸存者中其他潜在因素之间的关系。
在 2006 年至 2010 年参加英国生物银行的 502505 名参与者中,我们确定了 8429 名在 2006 年至 2016 年间被诊断为 BC 的患者,并通过 2016 年随访第二恶性肿瘤。在入组时收集了吸烟信息,并通过电子健康记录收集了治疗数据。多变量特定原因的 Cox 回归(CSC)评估了每个因素与 SPLC 风险之间的关系。
在 8429 名 BC 患者中,40 名(0.47%)在 45376 人年中发展为 SPLC。10 年累积 SPLC 发病率为 0.48%(95%CI=0.33%-0.62%)。CSC 分析证实了 SPLC 与既往吸烟状况之间的关联(调整后的危险比(aHR)=3.46(P<0.001)。分析表明,BC 幸存者每 10 个吸烟包年的 SPLC 风险增加 24%(aHR=每 10 包年 1.24,P=0.01)。SPLC 与其他变量之间的关联仍然没有统计学意义。我们应用 USPSTF 肺癌筛查资格标准,发现 80%的 40 名发展为 SPLC 的 BC 幸存者将不符合肺癌筛查条件。
在一项大型欧洲队列研究中,累积吸烟暴露与 BC 幸存者的 SPLC 风险显著相关。